The U.S. Food and Drug Administration (FDA) has issued a warning letter to Dabur India Limited following an inspection of the company’s drug manufacturing facility in Saily, Silvassa, Dadra and Nagar Haveli and Daman and Diu, India. The inspection, conducted from January 12 to 16, 2026, identified significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals.
The warning letter, dated July 24, 2026, was issued by the FDA’s Center for Drug Evaluation and Research (CDER) and addressed to Mohit Malhotra, Chief Executive Officer of Dabur India Limited. FDA identified deficiencies involving quality-unit oversight, data integrity, laboratory records, cleaning validation, equipment controls and process validation.
FDA Says Drug Products Are Considered Adulterated Under U.S. Law
According to the FDA, the company’s methods, facilities and controls for manufacturing, processing, packing and holding drugs did not conform to applicable CGMP requirements under 21 CFR Parts 210 and 211.
FDA therefore stated that the drug products manufactured at the facility are considered adulterated under Section 501(a)(2)(B) of the U.S. Federal Food, Drug, and Cosmetic Act.
The agency said the warning letter was based on findings from the January 2026 inspection as well as its review of Dabur’s February 4, 2026 response to the FDA Form 483.
1. FDA Flags Serious Data Integrity and Quality-System Failures
One of the most significant findings concerned the company’s quality control unit (QU). FDA said Dabur’s quality unit failed to adequately exercise its authority and responsibility over manufacturing operations, including ensuring the integrity of production records.
During the inspection, investigators requested an equipment-use logbook for a manufacturing unit. According to FDA, company management initially delayed producing the record. When a logbook was eventually provided, investigators determined that it appeared to have been newly created.
The original logbook was subsequently found in the document room.
FDA said comparison of the two records showed that the version initially provided to investigators had been falsified and omitted information concerning multiple U.S.-marketed OTC drug products.
The agency also identified discrepancies between original analytical data and values subsequently reported in batch manufacturing records or certificates of analysis.
These discrepancies involved quality attributes such as:
* Residue on ignition
* Melting range
* pH
* Viscosity
FDA noted that the inaccuracies did not involve out-of-specification results, but said the quality unit nevertheless approved records without ensuring that the data were consistent and accurate.
FDA Calls for a System-Wide Data Integrity Investigation
Dabur attributed the problems to inadequate documentation controls, insufficient oversight, transcription practices and insufficient quality-unit resources.
FDA, however, said the response did not adequately address the seriousness of the findings. Rather than treating the problems as isolated procedural errors, the agency said the findings indicated a potentially systemic failure in quality-unit oversight and quality culture.
FDA requested a comprehensive investigation into the extent of data inaccuracies, including an assessment covering manufacturing operations, laboratories and relevant systems. The agency also recommended interviews with current and former employees to identify the nature, scope and root causes of data integrity problems. FDA further requested a retrospective evaluation covering potential omissions, alterations, deletions, record destruction and non-contemporaneous record completion.
2. Missing Laboratory Records and Microbiology Data
FDA also identified deficiencies in Dabur’s laboratory recordkeeping. According to the warning letter, laboratory records did not contain complete data necessary to support testing and compliance with established specifications.
FDA investigators found that analytical notebooks documented microbiology plates as having been incubated, but the physical plates were not present in the incubators and there was no documented explanation for their absence or disposal.
The agency also said Dabur was unable to produce certain test procedures, analytical workbooks or test data sheets supporting reported certificate-of-analysis results for batches of U.S.-marketed drug products.
In addition, equipment logbooks did not contain required entries documenting the use of multiple instruments for particular batch-release testing.
Dabur told FDA that a microbiologist had inadvertently discarded missing microbiological plates because of inadequate training. The company said it retrained the employee, re-analyzed missing samples and introduced a controlled logbook to improve sample traceability.
FDA nevertheless concluded that the response did not adequately address the broader laboratory-system and data-integrity deficiencies.
The agency said reliable drug-quality decisions depend on complete, accurate and trustworthy laboratory data.
3. Cleaning Validation and Potential Cross-Contamination Concerns
Another major area of concern involved equipment cleaning and maintenance. FDA said Dabur failed to demonstrate that its cleaning practices were adequate to remove potential contaminants and prevent carryover of drug products when shared equipment was used.
For one non-dedicated manufacturing line, FDA said the cleaning-validation program relied exclusively on visual inspection rather than scientifically established maximum allowable carryover limits, quantitative residue testing and direct surface sampling of difficult-to-clean areas.
The agency also stated that cleaning validation had not been performed for another manufacturing line despite its use for multiple OTC drug products.
This is important from a pharmaceutical manufacturing perspective because inadequate cleaning of shared equipment can allow residues from one product to contaminate a subsequently manufactured product.
FDA therefore requested a comprehensive retrospective assessment of cleaning effectiveness and potential cross-contamination.
The assessment is expected to identify :
* Drug-product residues that could present a risk
* Equipment that may not have been adequately cleaned
* Drug products potentially affected by cross-contamination
* Products released for distribution that may have been impacted
* Weaknesses in existing cleaning procedures
* Worst-case products and cleaning conditions
* Difficult-to-clean equipment locations
* Maximum equipment hold times before cleaning
FDA also requested improvements to Dabur’s cleaning-validation program, including scientifically justified carryover limits and appropriate sampling and analytical methods.
4. Lack of Process Validation for OTC Drug Products
FDA identified another significant deficiency involving process validation. During the inspection, Dabur reportedly stated that it had not performed process validation for most of its OTC drug products manufactured on certain manufacturing lines. The company proposed developing process-validation plans and protocols using a campaign-based approach.
FDA considered the response inadequate because it did not provide specific schedules or completion timelines for the validation activities. The agency also said Dabur had not provided an adequate interim strategy, such as enhanced finished-product testing—to ensure the quality of products manufactured and distributed before completion of validation activities.
FDA emphasized that process validation is intended to demonstrate that a manufacturing process is capable of consistently producing drug products meeting predetermined quality requirements.
The agency requested a detailed validation program covering process performance qualification, equipment and facility qualification, intra-batch and inter-batch variation, and ongoing monitoring of manufacturing processes.
FDA also requested a timeline for process-performance qualification for each marketed drug product.
FDA Previously Recommended Removal of Certain Products From the U.S. Market
The warning letter also provides details about regulatory actions taken before the July 24 letter.
FDA said that on May 13, 2026, it held a teleconference with Dabur and recommended that the company consider removing certain batches from the U.S. market.
On June 2, 2026, Dabur issued a voluntary recall of certain products because of systemic quality failures at the facility.
However, FDA stated that another category of Dabur drug products had not been recalled as of the date of the warning letter.
The specific product names and quantities are redacted in the publicly available FDA warning letter.
FDA Places Dabur Products Under Import Alert
The regulatory consequences extend beyond the warning letter itself. FDA stated that it placed drugs and drug products offered for import into the United States from Dabur’s facility under Import Alert 66-40 on June 5, 2026.
Under the action described in the warning letter, products manufactured at the affected facility may be detained or refused admission into the United States if they appear to be adulterated because their manufacturing methods and controls do not conform to CGMP requirements.
FDA also warned that it may withhold approval of new applications or supplements listing the facility as a drug manufacturer until the identified CGMP violations have been adequately addressed and compliance has been confirmed.
The agency may also conduct another inspection to verify the effectiveness of corrective actions.
FDA Recommends an Independent CGMP Consultant
Given the nature of the findings, FDA recommended that Dabur engage a qualified independent consultant if the company intends to resume manufacturing drugs for the U.S. market.
The consultant should evaluate the facility’s operations and assist with CGMP remediation. FDA specifically requested a comprehensive six-system CGMP audit of the operation and an evaluation of whether corrective and preventive actions (CAPA) have been completed and are effective.
Importantly, FDA emphasized that hiring a consultant does not transfer responsibility away from Dabur’s management. The company’s executive management remains responsible for correcting the deficiencies and ensuring continuing CGMP compliance.
What FDA Wants Dabur to Do
The warning letter requires a broad remediation program rather than corrections limited to individual observations.
Among other actions, FDA requested that Dabur :
1. Conduct a comprehensive assessment of its documentation systems.
2. Establish a robust CAPA program addressing documentation and data integrity.
3. Strengthen the authority and resources of its quality unit.
4. Conduct a comprehensive investigation into data inaccuracies.
5. Perform retrospective assessments of potentially affected drug products.
6. Evaluate the potential impact of data-integrity failures on products already distributed in the U.S.
7. Strengthen laboratory data controls and recordkeeping.
8. Conduct a comprehensive assessment of cleaning effectiveness and cross-contamination risks.
9. Improve cleaning-validation procedures.
10. Establish appropriate process-validation programs and timelines.
11. Strengthen equipment and facility qualification.
12. Implement enhanced management oversight of CGMP operations.
13. Consider independent third-party audits to evaluate the effectiveness of remediation.
FDA also requested information about interim measures to protect patients and ensure drug quality, including potential customer notification, recalls, additional testing, stability monitoring and enhanced complaint monitoring where appropriate.
Dabur Given 15 Working Days to Respond
FDA instructed Dabur to respond in writing within 15 working days of receiving the warning letter.
The company was asked to explain what it had done to correct the violations and prevent their recurrence.
Where corrective actions could not be completed within that period, FDA requested that Dabur provide reasons for the delay along with a proposed completion schedule.
The warning letter does not represent a final determination that every drug manufactured by Dabur is unsafe. Rather, it identifies FDA's findings concerning the facility's CGMP compliance and requires the company to investigate, correct and prevent recurrence of the identified deficiencies.
Why This FDA Action Matters for the Indian Pharmaceutical Industry
The Dabur case highlights how U.S. regulators are increasingly focused not only on finished-product test results but also on the integrity of the systems and data used to demonstrate product quality.
For pharmaceutical manufacturers supplying the U.S. market, several lessons stand out.
Data integrity is a critical CGMP requirement: A product may meet an individual specification, but regulators still require reliable evidence demonstrating how that conclusion was reached.
Missing records, altered records, inconsistent source data or undocumented activities can undermine the credibility of an entire quality system.
Quality units must have real authority: FDA's observations demonstrate that a quality unit is expected to independently exercise its responsibilities rather than simply approve documents generated by manufacturing or laboratory personnel.
Cleaning validation cannot rely only on visual inspection: Shared manufacturing equipment requires scientifically justified cleaning controls capable of demonstrating that residues are adequately removed.
Process validation must demonstrate a state of control: Manufacturers need evidence that processes are capable of consistently producing products meeting established quality requirements—not merely evidence that individual finished batches passed testing.
CAPA must address root causes: FDA's criticism of Dabur's response is particularly important for pharmaceutical quality professionals.
The agency considered some proposed actions too narrow because they treated individual problems as isolated procedural failures rather than examining whether they reflected broader weaknesses in quality culture, management oversight and data governance.
A Broader Regulatory Signal
The FDA's action against Dabur comes amid continuing regulatory scrutiny of pharmaceutical manufacturing facilities around the world. FDA's warning-letter database identifies the Dabur action under CGMP/finished pharmaceuticals/adulterated, reflecting the agency's concerns about compliance with manufacturing requirements.
For Indian pharmaceutical manufacturers exporting medicines to the United States, the case reinforces the importance of maintaining inspection-ready systems at all times. The key message is that regulatory compliance extends far beyond passing laboratory tests. Data integrity, quality-unit independence, cleaning validation, process validation, documentation and management oversight are all interconnected components of pharmaceutical quality.
Conclusion
The July 24, 2026 FDA warning letter places significant regulatory pressure on Dabur India's affected manufacturing facility.
FDA identified serious concerns involving data integrity, falsified documentation, laboratory records, quality-unit oversight, cleaning validation and process validation. The agency also noted that certain products had already been voluntarily recalled and that products from the facility had been placed under Import Alert 66-40.
The next stage will depend on Dabur's corrective actions, the quality and completeness of its investigations, and FDA's assessment of whether the company's remediation efforts effectively address the systemic deficiencies identified during the inspection.
For the wider pharmaceutical industry, the case serves as another reminder that CGMP compliance is not simply about producing a drug that passes testing, it is about having reliable, scientifically sound and fully documented systems capable of proving that the drug was consistently manufactured under appropriate quality controls.
